FarmaKology-Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "firstname.lastname@example.org", and happy to have you featured on our newsletter+17K Subs.
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, China, Canada, UAE, Belgium, UK, and Taiwan sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
Best Buy is the #1 retailer for consumer electronics. We work hard every day to enrich the lives of consumers through technology, whether they come to us online, visit our stores or invite us into their homes.
Hundreds of women with advanced womb cancer in England are to be offered a new ‘lifeline’ option from today, as the NHS rolls out a life-extending new combination therapy that can halt the progression of the disease for twice as long as chemotherapy. The NHS has agreed landmark commercial deals for two drugs from different manufacturers, which will be used in combination to treat advanced endometrial cancer in between 500 and 750 women each year.
Regeneron Pharmaceuticals, Inc. applauds the United States Supreme Court’s unanimous opinion ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserted U.S. PCSK9 patent claims were invalid.
OmicsEdge has launched an industry leading drug discovery service that leverages Almaden’s g.nome™ platform to streamline the iteration process. The service makes it easy for labs to conduct a quick analysis of a patient or trial participant’s medical condition and genomics, gaining valuable insight in genomic criteria and how it affects elevated risk. The service can be used to significantly accelerate the drug discovery process and eliminate trial-and-error with abilities such as identifying causal variants that make ideal drug targets.
Shanghai Stock Exchange listed company HitGen Inc. announced today that it has entered into a research agreement with ARase Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways. HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also support ARase programs from hit-to-lead chemistry to pre-clinical development.
KSQ Therapeutics And Takeda Expand Strategic Immuno-Oncology Collaboration To Identify And Validate Novel Tumor Targets
KSQ Therapeutics, a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today that it has expanded its strategic collaboration with Takeda to research and validate novel tumor-intrinsic targets. Under the terms of the agreement, Takeda will provide KSQ with an upfront payment and an investment in the double-digit millions of dollars. KSQ is also eligible to receive up to $510 million in future payments if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the collaboration.
Buying Bitcoin is quick and easy with CoinSmart- The world's most accessible crypto exchange. Designed for beginners, built for experts. Instant verification, 24/7 support, fully registered, safe and secure.